Analysts expect Teladoc Inc (NYSE:TDOC) to announce earnings of ($0.36) per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have issued estimates for Teladoc’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.39). Teladoc posted earnings per share of ($0.55) in the same quarter last year, which indicates a positive year over year growth rate of 34.5%. The company is expected to announce its next earnings results on Wednesday, November 7th.
On average, analysts expect that Teladoc will report full year earnings of ($1.48) per share for the current year, with EPS estimates ranging from ($1.56) to ($1.12). For the next financial year, analysts forecast that the business will post earnings of ($1.04) per share, with EPS estimates ranging from ($1.44) to ($0.30). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Teladoc.
Teladoc (NYSE:TDOC) last released its quarterly earnings data on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.01. Teladoc had a negative return on equity of 19.10% and a negative net margin of 37.78%. The business had revenue of $94.60 million for the quarter, compared to the consensus estimate of $91.56 million. During the same quarter in the prior year, the business posted ($0.28) EPS. The business’s revenue for the quarter was up 112.1% on a year-over-year basis.
In other Teladoc news, insider Adam C. Vandervoort sold 5,549 shares of the stock in a transaction that occurred on Wednesday, August 8th. The stock was sold at an average price of $67.25, for a total transaction of $373,170.25. Following the completion of the sale, the insider now directly owns 2,934 shares of the company’s stock, valued at approximately $197,311.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Lewis Levy sold 1,285 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $70.80, for a total value of $90,978.00. The disclosure for this sale can be found here. Insiders have sold a total of 228,745 shares of company stock worth $14,755,952 in the last 90 days. 3.95% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of TDOC. Global Thematic Partners LLC acquired a new stake in Teladoc during the 1st quarter worth approximately $51,465,000. Bank of America Corp DE lifted its position in Teladoc by 82.8% during the 2nd quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock worth $109,318,000 after acquiring an additional 853,076 shares during the period. Summit Partners L P acquired a new stake in Teladoc during the 2nd quarter worth approximately $37,772,000. Westwood Management Corp IL lifted its position in Teladoc by 1,342.6% during the 2nd quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock worth $34,000,000 after acquiring an additional 545,100 shares during the period. Finally, Bellevue Group AG lifted its position in Teladoc by 997.2% during the 1st quarter. Bellevue Group AG now owns 515,694 shares of the health services provider’s stock worth $20,782,000 after acquiring an additional 468,694 shares during the period.
Shares of TDOC traded up $1.85 during mid-day trading on Thursday, reaching $72.60. The company’s stock had a trading volume of 1,118,000 shares, compared to its average volume of 1,197,384. Teladoc has a 12-month low of $27.30 and a 12-month high of $73.25. The company has a market cap of $5.00 billion, a P/E ratio of -43.35 and a beta of 0.40. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.14 and a current ratio of 3.14.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Recommended Story: Technical Analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.